Metabolic Disorders Therapeutics is a drug used to treat the symptoms of metabolic disorders caused by a variety of causes.
The “Metabolic Disorders Therapeutics Industry Forecast” looks at past sales and reviews total world Metabolic Disorders Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected Metabolic Disorders Therapeutics sales for 2023 through 2029. With Metabolic Disorders Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Metabolic Disorders Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global Metabolic Disorders Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Metabolic Disorders Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Metabolic Disorders Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Metabolic Disorders Therapeutics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Metabolic Disorders Therapeutics.
The global Metabolic Disorders Therapeutics market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
Due to the increasing pressure of modern life and the spread of unhealthy lifestyles, the global metabolic disorder treatment market will continue to grow strongly during the forecast period.
This report presents a comprehensive overview, market shares, and growth opportunities of Metabolic Disorders Therapeutics market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Metachromatic Leukodystrophy
Globoid Leukodystrophy
Hepatic Encephalopathy
Others
Segmentation by application
Diabetes
Obesity
Hypercholesterolemia
Lysosomal Storage Diseases
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AbbVie
Novo Nordisk
Actelion Pharmaceuticals
Sanofi
Biocon
Merck
Boehringer Ingelheim
AstraZeneca
CymaBay Therapeutics
Eli Lilly and Company
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Metabolic Disorders Therapeutics Market Size 2018-2029
2.1.2 Metabolic Disorders Therapeutics Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Metabolic Disorders Therapeutics Segment by Type
2.2.1 Metachromatic Leukodystrophy
2.2.2 Globoid Leukodystrophy
2.2.3 Hepatic Encephalopathy
2.2.4 Others
2.3 Metabolic Disorders Therapeutics Market Size by Type
2.3.1 Metabolic Disorders Therapeutics Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Metabolic Disorders Therapeutics Market Size Market Share by Type (2018-2023)
2.4 Metabolic Disorders Therapeutics Segment by Application
2.4.1 Diabetes
2.4.2 Obesity
2.4.3 Hypercholesterolemia
2.4.4 Lysosomal Storage Diseases
2.4.5 Others
2.5 Metabolic Disorders Therapeutics Market Size by Application
2.5.1 Metabolic Disorders Therapeutics Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Metabolic Disorders Therapeutics Market Size Market Share by Application (2018-2023)
3 Metabolic Disorders Therapeutics Market Size by Player
3.1 Metabolic Disorders Therapeutics Market Size Market Share by Players
3.1.1 Global Metabolic Disorders Therapeutics Revenue by Players (2018-2023)
3.1.2 Global Metabolic Disorders Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Metabolic Disorders Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Metabolic Disorders Therapeutics by Regions
4.1 Metabolic Disorders Therapeutics Market Size by Regions (2018-2023)
4.2 Americas Metabolic Disorders Therapeutics Market Size Growth (2018-2023)
4.3 APAC Metabolic Disorders Therapeutics Market Size Growth (2018-2023)
4.4 Europe Metabolic Disorders Therapeutics Market Size Growth (2018-2023)
4.5 Middle East & Africa Metabolic Disorders Therapeutics Market Size Growth (2018-2023)
5 Americas
5.1 Americas Metabolic Disorders Therapeutics Market Size by Country (2018-2023)
5.2 Americas Metabolic Disorders Therapeutics Market Size by Type (2018-2023)
5.3 Americas Metabolic Disorders Therapeutics Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Metabolic Disorders Therapeutics Market Size by Region (2018-2023)
6.2 APAC Metabolic Disorders Therapeutics Market Size by Type (2018-2023)
6.3 APAC Metabolic Disorders Therapeutics Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Metabolic Disorders Therapeutics by Country (2018-2023)
7.2 Europe Metabolic Disorders Therapeutics Market Size by Type (2018-2023)
7.3 Europe Metabolic Disorders Therapeutics Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Metabolic Disorders Therapeutics by Region (2018-2023)
8.2 Middle East & Africa Metabolic Disorders Therapeutics Market Size by Type (2018-2023)
8.3 Middle East & Africa Metabolic Disorders Therapeutics Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Metabolic Disorders Therapeutics Market Forecast
10.1 Global Metabolic Disorders Therapeutics Forecast by Regions (2024-2029)
10.1.1 Global Metabolic Disorders Therapeutics Forecast by Regions (2024-2029)
10.1.2 Americas Metabolic Disorders Therapeutics Forecast
10.1.3 APAC Metabolic Disorders Therapeutics Forecast
10.1.4 Europe Metabolic Disorders Therapeutics Forecast
10.1.5 Middle East & Africa Metabolic Disorders Therapeutics Forecast
10.2 Americas Metabolic Disorders Therapeutics Forecast by Country (2024-2029)
10.2.1 United States Metabolic Disorders Therapeutics Market Forecast
10.2.2 Canada Metabolic Disorders Therapeutics Market Forecast
10.2.3 Mexico Metabolic Disorders Therapeutics Market Forecast
10.2.4 Brazil Metabolic Disorders Therapeutics Market Forecast
10.3 APAC Metabolic Disorders Therapeutics Forecast by Region (2024-2029)
10.3.1 China Metabolic Disorders Therapeutics Market Forecast
10.3.2 Japan Metabolic Disorders Therapeutics Market Forecast
10.3.3 Korea Metabolic Disorders Therapeutics Market Forecast
10.3.4 Southeast Asia Metabolic Disorders Therapeutics Market Forecast
10.3.5 India Metabolic Disorders Therapeutics Market Forecast
10.3.6 Australia Metabolic Disorders Therapeutics Market Forecast
10.4 Europe Metabolic Disorders Therapeutics Forecast by Country (2024-2029)
10.4.1 Germany Metabolic Disorders Therapeutics Market Forecast
10.4.2 France Metabolic Disorders Therapeutics Market Forecast
10.4.3 UK Metabolic Disorders Therapeutics Market Forecast
10.4.4 Italy Metabolic Disorders Therapeutics Market Forecast
10.4.5 Russia Metabolic Disorders Therapeutics Market Forecast
10.5 Middle East & Africa Metabolic Disorders Therapeutics Forecast by Region (2024-2029)
10.5.1 Egypt Metabolic Disorders Therapeutics Market Forecast
10.5.2 South Africa Metabolic Disorders Therapeutics Market Forecast
10.5.3 Israel Metabolic Disorders Therapeutics Market Forecast
10.5.4 Turkey Metabolic Disorders Therapeutics Market Forecast
10.5.5 GCC Countries Metabolic Disorders Therapeutics Market Forecast
10.6 Global Metabolic Disorders Therapeutics Forecast by Type (2024-2029)
10.7 Global Metabolic Disorders Therapeutics Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 AbbVie
11.1.1 AbbVie Company Information
11.1.2 AbbVie Metabolic Disorders Therapeutics Product Offered
11.1.3 AbbVie Metabolic Disorders Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 AbbVie Main Business Overview
11.1.5 AbbVie Latest Developments
11.2 Novo Nordisk
11.2.1 Novo Nordisk Company Information
11.2.2 Novo Nordisk Metabolic Disorders Therapeutics Product Offered
11.2.3 Novo Nordisk Metabolic Disorders Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Novo Nordisk Main Business Overview
11.2.5 Novo Nordisk Latest Developments
11.3 Actelion Pharmaceuticals
11.3.1 Actelion Pharmaceuticals Company Information
11.3.2 Actelion Pharmaceuticals Metabolic Disorders Therapeutics Product Offered
11.3.3 Actelion Pharmaceuticals Metabolic Disorders Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Actelion Pharmaceuticals Main Business Overview
11.3.5 Actelion Pharmaceuticals Latest Developments
11.4 Sanofi
11.4.1 Sanofi Company Information
11.4.2 Sanofi Metabolic Disorders Therapeutics Product Offered
11.4.3 Sanofi Metabolic Disorders Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Sanofi Main Business Overview
11.4.5 Sanofi Latest Developments
11.5 Biocon
11.5.1 Biocon Company Information
11.5.2 Biocon Metabolic Disorders Therapeutics Product Offered
11.5.3 Biocon Metabolic Disorders Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Biocon Main Business Overview
11.5.5 Biocon Latest Developments
11.6 Merck
11.6.1 Merck Company Information
11.6.2 Merck Metabolic Disorders Therapeutics Product Offered
11.6.3 Merck Metabolic Disorders Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Merck Main Business Overview
11.6.5 Merck Latest Developments
11.7 Boehringer Ingelheim
11.7.1 Boehringer Ingelheim Company Information
11.7.2 Boehringer Ingelheim Metabolic Disorders Therapeutics Product Offered
11.7.3 Boehringer Ingelheim Metabolic Disorders Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Boehringer Ingelheim Main Business Overview
11.7.5 Boehringer Ingelheim Latest Developments
11.8 AstraZeneca
11.8.1 AstraZeneca Company Information
11.8.2 AstraZeneca Metabolic Disorders Therapeutics Product Offered
11.8.3 AstraZeneca Metabolic Disorders Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 AstraZeneca Main Business Overview
11.8.5 AstraZeneca Latest Developments
11.9 CymaBay Therapeutics
11.9.1 CymaBay Therapeutics Company Information
11.9.2 CymaBay Therapeutics Metabolic Disorders Therapeutics Product Offered
11.9.3 CymaBay Therapeutics Metabolic Disorders Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 CymaBay Therapeutics Main Business Overview
11.9.5 CymaBay Therapeutics Latest Developments
11.10 Eli Lilly and Company
11.10.1 Eli Lilly and Company Company Information
11.10.2 Eli Lilly and Company Metabolic Disorders Therapeutics Product Offered
11.10.3 Eli Lilly and Company Metabolic Disorders Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Eli Lilly and Company Main Business Overview
11.10.5 Eli Lilly and Company Latest Developments
12 Research Findings and Conclusion
*If Applicable.